Jefferies Presentation
About Us
Developing high-value products for patients in niche indications with significant unmet medical need
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
NOW FDA APPROVED
TARPEYO (budesonide) delayed release capsules
TARPEYO has been approved only by the US FDA and only for use in the United States. All information concerning TARPEYO on this website is intended solely for residents of the United States.
Calliditas vision is to leverage its interdisciplinary expertise in pharmaceutical product development to identify, develop and commercialize novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
On May 18, 2022, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2022.
Audio cast with teleconference, Q1 2022, May 18, 2022, 14:30 CET
Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden
Company number: 556659-9766
© Calliditas Therapeutics AB 2022